The immune response to SARS-CoV-2. Focus on severe COVID-19 pathogenesis

Pawliczak, Rafał

doi:10.5114/pja.2020.99243

Cited by 3 publications

(3 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In COVID-19, pattern recognition receptors (PRRs), such as toll-like receptors (TLR-7, TLR-8), NOD-like receptors (NRL) and RIG-I-like receptors (RLR), recognise viral antigens, which results in production of IFN I, III and several chemokines by infected cells [20]. Dendritic cells and macrophages are APCs.…”

Section: Pathophysiology Of Multiple Sclerosis Vs Pathophysiology Of Covid-19mentioning

confidence: 99%

Multiple sclerosis immunomodulatory therapies tested for effectiveness in COVID-19

Adamczyk

Morawiec

Arendarczyk

et al. 2021

Neurol Neurochir Pol.

View full text Add to dashboard Cite

Introduction:The global pandemic of COVID-19 began in Wuhan, China in December 2019. Research into effective therapies has been conducted worldwide. Currently, there is no antiviral treatment and many patients develop a severe course of the disease, including severe respiratory failure. Due to similar pathomechanisms of inflammation in multiple sclerosis (MS) and COVID-19, immunomodulatory drugs that are registered for the treatment of MS are under study in the SARS-CoV-2 infection in clinical trials.Materials and methods: Using clinicaltrials.gov, we found information related to ongoing clinical studies on potential drugs for COVID-19 which are also used in MS therapy. The outcomes of several trials were published on pubmed.ncbi.nlm.nih.gov.Results: There were 18 clinical trials evaluating the effectiveness and safety of interferon-β, fi ngolimod, or leflunomide in COVID-19. Some trial outcomes available at pubmed.ncbi.nlm.nih.gov suggested an association of these drug treatments with improvements in signs and symptoms, and the disease course. Conclusion:The administration of immunomodulatory drugs in COVID-19 may result in potential beneficial effects probably associated with their anti-inflammatory and antiviral properties. Further research is warranted to confirm the long-term effects of immunomodulatory therapies in patients with COVID-19.

show abstract

Section: Pathophysiology Of Multiple Sclerosis Vs Pathophysiology Of Covid-19mentioning

confidence: 99%

Multiple sclerosis immunomodulatory therapies tested for effectiveness in COVID-19

Adamczyk

Morawiec

Arendarczyk

et al. 2021

Neurol Neurochir Pol.

View full text Add to dashboard Cite

show abstract

“…A vital role in the pathogenesis of this disease is played by the capacity of the coronavirus cell to infect the immune system and its different parts. For example, lymphocyte infection has a crucial role in the virally induced pathogenesis of SARS-CoV-2 [27] .…”

Section: Introductionmentioning

confidence: 99%

Covid-19 a triggering factor of autoimmune and multi-inflammatory diseases

et al. 2023

View full text Add to dashboard Cite

“…An important step in the treatment and control of a COVID disease is monitoring the human immune response to a SARS-CoV virus. The presence of an immune response and the amount of antibody circulating in the body are often critical tools for assessing a patient's individual condition and disease history, as well as for understanding the mechanisms of regional and global spread of the pathogen (Boechat et al 2021 ; Pawliczak 2020 ).…”

Section: Introductionmentioning

confidence: 99%

Development of colorimetric cellulose-based test-strip for the rapid detection of antibodies against SARS-CoV2 virus

Correia

Sousa

et al. 2022

Cellulose

View full text Add to dashboard Cite

Given the pandemic situation, there is an urgent need for an accurate test to monitor antibodies anti-SARS-CoV-2, providing crucial epidemiological and clinical information to monitor the evolution of coronavirus disease in 2019 (COVID-19) and to stratify the immunized and asymptomatic population. Therefore, this paper describes a new cellulose-based test strip for rapid and cost-effective quantitative detection of antibodies to SARS-CoV2 virus by colorimetric transduction. For this purpose, Whatman paper was chemically modified with sodium metaperiodate to introduce aldehyde groups on its surface. Subsequently, the spike protein of the virus is covalently bound by forming an imine group. The chemical control of cellulose paper modification was evaluated by Fourier transform infrared spectroscopy, thermogravimetry and contact angle analysis. Colorimetric detection of the antibodies was performed by a conventional staining method using Ponceau S solution as the dye. Color analysis was performed after image acquisition with a smartphone using Image J software. The color intensity varied linearly with the logarithm of the anti-S concentration (from 10 ng/mL to 1 μg/mL) in 500-fold diluted serum samples when plotted against the green coordinate extracted from digital images. The test strip was selective in the presence of nucleocapsid antibodies, urea, glucose, and bovine serum albumin with less than 15% interference, and detection of antibodies in human serum was successfully performed. Overall, this is a simple and affordable design that can be readily used for mass population screening and does not require sophisticated equipment or qualified personnel. Supplementary Information The online version contains supplementary material available at 10.1007/s10570-022-04808-y.

show abstract

The immune response to SARS-CoV-2. Focus on severe COVID-19 pathogenesis

Cited by 3 publications

References 42 publications

Multiple sclerosis immunomodulatory therapies tested for effectiveness in COVID-19

Multiple sclerosis immunomodulatory therapies tested for effectiveness in COVID-19

Covid-19 a triggering factor of autoimmune and multi-inflammatory diseases

Development of colorimetric cellulose-based test-strip for the rapid detection of antibodies against SARS-CoV2 virus

Contact Info

Product

Resources

About